Metformin: a modulator of bevacizumab activity in cancer? A case report

Recurrent type I endometrial cancer ((EC)) has poor prognosis and demands novel therapeutic approaches. Bevacizumab, a VEGF-A neutralizing monoclonal antibody, has shown clinical activity in this setting. To our knowledge, however, although some diabetic cancer patients treated with bevacizumab may...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Indraccolo, Stefano, Randon, Giovanni, Zulato, Elisabetta, Nardin, Margherita, Aliberti, Camillo, Pomerri, Fabio, Casarin, Alessandra, Nicoletto, Maria Ornella
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Bedside to Bench Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4623111/
https://ncbi.nlm.nih.gov/pubmed/25607951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2014.1002366
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados